UK consumer goods giant Reckitt Benckiser LLC created its K-Y-branded premature ejaculation spray without stealing trade secrets from a small pharmaceutical company, according to a jury in a New Jersey federal court.
Absorption Pharmaceuticals LLC failed to show that the information at issue was protected as a trade secret or that Reckitt acted dishonestly during the company's acquisition negotiations, according to the jury.
Las Vegas-based Absorption had sought more than $450 million in damages. Reckitt had no
In a 2017 lawsuit, Absorption claimed that its Promescent lidocaine spray could treat premature ejaculation in the same way that Viagra treated erectile dysfunction. Absorption claimed it shared secrets with Reckitt during discussions about a possible acquisition.
Senior Reckitt workers tried samples of Promescent and indicated it actually works, according to the lawsuit. Absorption allegedly supplied thousands of bottles of Promescent to Reckitt for testing, according to the lawsuit.
Reckitt and Absorption finished their negotiations in 2015, and K-Y Duration commenced production in 2016. Reckitt also allegedly coerced Amazon and Target to lower Promescent's visibility in an attempt to drive the company out of business.
Reckitt also committed fraud, according to the lawsuit, by making misleading assertions about its intentions to buy Absorption, which persuaded it to reveal its secrets and turn down an offer to be acquired by another business.
In a court filing this month, Reckitt contended that it had not misled Absorption and that it had failed to discover any stolen trade secrets.


FDA Approves Mitapivat for Anemia in Thalassemia Patients
Tesla Launches New Model Y Variant in the US Starting at $41,990
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Supreme Court Tests Federal Reserve Independence Amid Trump’s Bid to Fire Lisa Cook
RBA Raises Interest Rates by 25 Basis Points as Inflation Pressures Persist
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Google Halts UK YouTube TV Measurement Service After Legal Action
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft
S&P 500 Rises as AI Stocks and Small Caps Rally on Strong Earnings Outlook 



